Stockhub

Alzamend Neuro, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

13 August 2022

11 August 2022

26 July 2022

  • curprev 16:5316:53, 26 July 2022‎ Chris talk contribs‎ 818 bytes +818‎ Created page with "Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases,..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Alzamend_Neuro,_Inc.’